Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

DDAVP treatment combined with FVIII clotting factor concentrates in patients with mild hemophilia A

- candidate number22808
- NTR NumberNTR5383
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR27-aug-2015
- Secondary IDsNL53686.078.15  toetsing online
- Public TitleDDAVP treatment combined with FVIII clotting factor concentrates in patients with mild hemophilia A
- Scientific TitleDDAVP treatment combined with FVIII clotting factor concentrates in patients with mild hemophilia A
- hypothesisDDAVP and FVIII concentrate combination treatment will be able to be implemented as standard care for mild hemophilia A patients in the perioperative setting
- Healt Condition(s) or Problem(s) studiedHemophily A, Surgery, Pharmacokinetics, Desmopressin
- Inclusion criteria- Mild hemophilia A patients (FVIII > 0.05 IU/mL)
- In need of surgery
- Age minimally 12 and maximally 70 years at study inclusion date
- Need for perioperative clotting factor concentrates
- Treatment duration with FVIII-concentrates of at least 48 hours
- Results of FVIII levels after a DDAVP test dose, or if test results are not available, willingness to undergo a DDAVP test
- Male gender
- (Parental) informed consent
- Exclusion criteria- Patients with other congenital or acquired hemostatic abnormalities
- Very low response to DDAVP after 1 hour – absolute increase in FVIII < 0.2 IU/mL
- Detectable FVIII inhibiting antibodies (>0.2 BU) in medical history or preoperatively, unless successfully treated with immunotolerance therapy
- Contraindications for DDAVP, e.g. cardiovascular disease (see appendix IV)
- Use of co-medication that has an interaction with DDAVP (see appendix IV)
- Intolerance to previous DDAVP administrations
- DDAVP not advisable due to the type of surgery according to the hematologist and/or surgeon
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- group[default]
- TypeSingle arm
- Studytypeintervention
- planned startdate 1-feb-2016
- planned closingdate1-jun-2018
- Target number of participants50
- InterventionsDDAVP and FVIII concentrate combination treatment
- Primary outcomeThe main endpoint will be the proportion of patients within FVIII target levels with DDAVP and FVIII concentrate combination treatment in the first 72 hours after surgery, without adding off-protocol FVIII concentrates
- Secondary outcome- A population based pharmacokinetic model
- Number and nature of adverse events during combined treatment
- Incidence & severity of bleeding
- Incidence of thrombosis
- Incidence and extent of tachyphylaxis
- Economical evaluation
- Experienced quality of care
- Timepointspreoperatively
postoperatively 0-72 hours
postoperatively 72-144 hours
postoperatively > 144 hours - 90 days
- Trial web site
- statusopen: patient inclusion
- Sponsor/Initiator Erasmus Medical Center, Rotterdam
- Funding
(Source(s) of Monetary or Material Support)
ZON-MW, The Netherlands Organization for Health Research and Development, Ferring Pharmaceuticals Denmark
- Publications
- Brief summarySummary

Rationale: Hemophilia A is a rare X-linked hereditary bleeding disorder in which the secondary hemostasis is affected by a deficiency in clotting factor VIII (FVIII). As a consequence, patients may suffer from excessive bleeding in response to minor (surgical) trauma or injury. In all hemophilia A patients, perioperative factor concentrate replacement therapy is required, aiming for physiological FVIII plasma levels during up to 6 weeks. In mild hemophilia A patients, surgical procedures are the main reason for intensive treatment with FVIII concentrates. Treatment with FVIII concentrates is effective, but highly expensive. On average, treatment with FVIII concentrates costs €17,520 per mild hemophilia A patient, per surgical procedure. Moreover, exposure to exogenous FVIII may cause the development of FVIII neutralizing antibodies. Recent studies have shown this incidence is higher than realized previously. Neutralizing antibodies are a major challenge in hemophilia A patients, as they lead to ineffectiveness of administered FVIII concentrates and cause subsequent bleeding complications with an increased mortality. Sometimes, these neutralizing antibodies inhibit patients’ endogenous FVIII, reducing endogenous FVIII levels below 0.01 IU/ml and a concomitant phenotype of severe hemophilia. Therefore, it is of utmost importance to reduce administration of FVIII concentrates when not strictly indicated and when potential alternatives are available. More specifically, the release of endogenous FVIII, present in mild hemophilia A patients, can be stimulated by the on-market drug desmopressin (DDAVP). These endogenous FVIII plasma levels, temporarily increased by DDAVP, can be supplemented with FVIII concentrate in order to reach perioperative FVIII target levels, as prescribed by National Consensus.

Objective: The primary objective is to assess the proportion of patients within FVIII target levels with DDAVP and FVIII concentrate combination treatment in mild hemophilia A patients in the first 72 hours postoperatively. Secondary objectives are to acquire data to improve a population based pharmacokinetic (PK) model and to perform an economical evaluation to quantify potential cost reduction.

Study design: A multicenter non-randomized clinical trial in the Netherlands

Study population: Fifty mild hemophilia A patients (FVIII >0.05 IU/mL), between 12-70 years of age, undergoing a surgical procedure and requiring perioperative FVIII replacement therapy for at least 48 hours.

Intervention: Included patients will receive DDAVP and FVIII concentrate combination treatment in the perioperative setting. The FVIII concentrate dose required to reach perioperative FVIII target levels after DDAVP infusion, will be calculated based on a PK population model, constructed by Bayesian analysis using NON-MEM® statistical software prior to the observational trial.

Main study parameters/endpoints: Primary endpoint is the proportion of patients that reach the set FVIII target levels during the first 72 hours postoperatively when treated with DDAVP and FVIII concentrate combination treatment.
- Main changes (audit trail)25-juli-2017 -IK:

"Mild hemophilia A patients (FVIII > 0.05 IU/mL)"
replaced by
"Non-severe hemophilia A patients (FVIII ≥ 0.01 IU/mL)"
- RECORD27-aug-2015 - 25-jul-2017

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar